FLULIEVA 50 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. It is intracellularly converted to fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to suppression of DNA synthesis and apoptosis. It is widely used in hematologic malignancies.

Fludarabine Phosphate is indicated for:

1. Chronic Lymphocytic Leukemia (CLL)
     – Relapsed or refractory disease

2. Indolent Non-Hodgkin’s Lymphoma

3. Hairy Cell Leukemia (off-label)

4. Conditioning regimens for stem cell transplantation

Common side effects:

•  Severe myelosuppression

•  Nausea, vomiting

•  Fatigue

•  Fever

Serious side effects:

•  Profound immunosuppression → opportunistic infections

•  Neurotoxicity (confusion, seizures at high doses)

•  Autoimmune hemolytic anemia

 Regular monitoring of CBC is mandatory; infection prophylaxis is often required.

Dosage is calculated based on body surface area (BSA).

Standard dosing:

•  25 mg/m²/day IV for 5 days

•  Repeated every 28 days

50 mg strength is commonly used for adult dosing and combination regimens.


NOTE: This medicine should be taken only under a doctor’s supervision.